Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03235050 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 834
- Enrollment target
NCT03235050 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 834 participants.
The verdict
NCT03235050, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 834 participants
- Enrollment target
Study Summary
This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
Interventions
- DRUG Placebo
- DRUG Liraglutide
- DRUG MEDI0382 low dose
- DRUG MEDI0382 mid dose
- DRUG MEDI0382 high dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 834 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2019-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03235050
The ClinicalTrials.gov registry entry for NCT03235050 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 834 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT03235050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03235050 about?
NCT03235050 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes". This study is designed to evaluate the dose range for MEDI0382 with respect to blood glucose control and weight loss effects, as well as to further explore the safety profile of MEDI0382
What is the current status of trial NCT03235050?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 834 participants. The study started on 2017-08-02. Estimated completion is 2019-06-14.
What interventions are being tested in trial NCT03235050?
The interventions under investigation include: Placebo (DRUG), Liraglutide (DRUG), MEDI0382 low dose (DRUG), MEDI0382 mid dose (DRUG), MEDI0382 high dose (DRUG).
Who is sponsoring clinical trial NCT03235050?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.